Oral Answers to Questions

Greg Mulholland Excerpts

Tuesday 24th March 2015 Commons Chamber

[Greg Clark]

The hon. Lady’s initial question was about how the Government’s policies on devolution and constitutional reform have benefited her constituents and I set that out in terms. I would have thought that she would want to recognise that, as did the hon. Member for Blackley and Broughton (Graham Stringer). The front page of the Manchester Evening News put it in this way: “We’re All Winners!” Part of the gain for Manchester is that local people can make more of the local decisions, including those on housing, as I mentioned in my previous answer.

[Greg Mulholland (Leeds North West) (LD)]

T1. If he will make a statement on his departmental responsibilities.

[The Deputy Prime Minister (Mr Nick Clegg)]

As Deputy Prime Minister, I support the Prime Minister on the full range of Government policy initiatives. I take special responsibility for the Government’s programme of political and constitutional reform.

[Greg Mulholland]

I thank my right hon. Friend for that answer. I urge him to intervene in the campaign to get the drugs that are needed for those with Morquio syndrome, Duchenne muscular dystrophy and tuberous sclerosis. The Prime Minister said that there should be continuity of treatment, yet we have found out that that will not be delivered by the Department of Health. Katy Brown, the mother of my six-year-old constituent Sam Brown, has said that that is at best “misleading, at worst underhand”. This situation is disgraceful. We need to fund those drugs now on an interim basis. Will my right hon. Friend speak to the Prime Minister and get it sorted this week?

[The Deputy Prime Minister]

I pay tribute to my hon. Friend for the way he has sought to represent his constituent Sam Brown, and all the other children and their families who are—quite understandably—concerned about the continued provision of these drugs. As he heard from the Prime Minister when he raised the matter at Prime Minister’s questions two weeks ago, the understanding is that NHS England is conducting a review that will conclude by the end of next month. In the meantime, drug companies will continue with the provision of these drugs until the end of May, so that continuity is assured. Given my hon. Friend’s concerns, I will undertake to look urgently at the matter again.